Iovance Biotherapeutics (NASDAQ:IOVA) has seen significant options trading activity, with a bullish sentiment from financial giants. Analysis revealed 23 unusual trades, with a majority being bullish. The trading focused on a price range between $5.0 and $22.0. The largest trades were bearish call sweeps with expiration dates ranging from 2024 to 2024 and strike prices between $7.50 and $17.50. The company, a clinical-stage biopharmaceutical firm, is preparing for potential U.S. regulatory approval of its T-cell therapy for solid tumor cancers. The stock price is up 3.49% at $16.32, with an RSI indicating it may be overbought. Analysts have set an average target price of $22.4, with ratings ranging from Buy to Overweight.